News

Filter

Current filters:

Johnson & JohnsonRemicade

1 to 9 of 135 results

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

04-12-2014

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyinfliximabJohnson & JohnsonNew ZealandPricingRemicade

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan

01-12-2014

Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

New Zealand proposal for sole supply of Remicade in DHB hospitals

New Zealand proposal for sole supply of Remicade in DHB hospitals

31-10-2014

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesceftaroline fosamilFinancialJanssen-CilagJohnson & JohnsonNew ZealandPharmaceuticalPricingRemicade

Celltrion files for US FDA approval of Remsima biosimilar

Celltrion files for US FDA approval of Remsima biosimilar

13-08-2014

South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US…

BiosimilarsBiotechnologyCellTrionClinical researchInflammatory diseasesinfliximabJanssen BiotechJohnson & JohnsonPatentsRegulationRemicadeRemsimaUSA

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

30-01-2014

The imminent entry of several companies, including big pharma, small biotech and generic participants,…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesEuropeHospiraJohnson & JohnsonMarkets & MarketingNorth AmericaRemicadeUSA

1 to 9 of 135 results

COMPANY SPOTLIGHT

Menarini

Back to top